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December 20101732 Abstractstogenarians were more likely to undergo CAS (as opposed to CEA) than
asymptomatic younger patients (10.1% vs 5.7%, P  .001). In separate
analysis of octogenarians alone, it was noted that they had a significantly
higher rate of periprocedural stroke with CAS than with CEA (2.2% vs 1.1%,
P  .01). The increased rate of stroke with CAS as opposed to CEA was
noted in both asymptomatic (1.9% vs 0.9%, P .04) and symptomatic (5.2%
vs 2.3%, P  .18) octogenarians.
Conclusions: Nationally, octogenarians comprise nearly 20% of pa-
tients undergoing carotid revascularization procedures, despite concern
regarding the benefits of these procedures in older patients, particularly
when asymptomatic. In spite of additional specific concerns regarding the
complication rate of CAS in patients older than 80 years of age, asymptom-
atic octogenarians underwent CAS as opposed to CEA significantly more
frequently than younger patients. However, their periprocedural stroke rate
overall was equally low when compared to younger patients. Furthermore,
among octogenarians, the rate of periprocedural stroke was significantly
higher with CAS than with CEA, and this remained a significant finding
when asymptomatic cases were separately examined. CEA may be the
treatment of choice for properly selected octogenarians, unless compelling
reasons exist to perform CAS.
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Background: Improved renal function after renal artery bypass surgery
has been associated with improved dialysis-free survival. Unfortunately,
renal artery bypass in patients with ischemic nephropathy carries a 4% to 7%
operative mortality rate. Renal artery stenting (RAS) offers a lower risk of
mortality, but the clinical response rates for RAS have been disappointing.
We surmise that the poor results for RAS are related to inadequate patient
selection. The purpose of this study was to identify preoperative clinical
features that predict a durable improvement in renal function with RAS.
Methods: The study cohort consisted of 43 patients with renal insuf-
ficiency (serum creatinine  1.5 mg/dL) who underwent RAS for renal
salvage. Patients were categorized as “responders” if estimated glomerular
filtration rate (eGFR) at last follow-up was improved 20% or more over
baseline. Patients with stable or worse renal function after RAS were labeled
“nonresponders.” For the purpose of calculating changes in eGFR, patients
on dialysis were represented by an eGFR of 10 mL/min/1.73 m2. Renal
volume was estimated as kidney length  width  depth/2.
Results: The median age of the cohort was 69 years (interquartile
range, IQR, 61-73 years). Median preoperative serum creatinine was 1.8
mg/dL (IQR 1.6-2.3), and median eGFR was 39 mL/min/1.73 m2 (IQR
21-46). With stenting, 11 of 43 patients (25.6%) derived a durable improve-
ment in renal function at a median follow-up of 26 months (IQR 16-36
months). Responders enjoyed a 54% improvement in renal function from
baseline, while nonresponders had a 7% decrement in renal function (P 
.0001). Responders had a higher diastolic blood pressure, higher baseline
serum creatinine, lower eGFR, and a steeper decline in renal function prior
to RAS (Table). Kidney length, width, depth, and volume were not signif-
icantly different between responders and nonresponders (Table). Logistic
regression analysis identified the rate of decline of renal function prior to
stenting as the only independent predictor of improved renal function after
RAS (odds ratio 16.7, 95% confidence interval 1.9-147.0; P  .011).
Indeed, the rate of decline in eGFR per week was more than 18-fold greater
for responders than nonresponders (3.4% vs 0.18% decline in eGFR per
week; P  .0001).
Conclusions: The current study found that a steep decline in preop-
erative renal function portends a higher likelihood of renal salvage from RAS
among patients with renal insufficiency. Incorporating this finding into
patient selection may improve outcomes for RAS.
Variables Responders Nonresponders P value
Age 71 years 68 years .62
Gender 55% male 66% male .43
Systolic blood
pressure
172 mm Hg 145 mm Hg .15
Diastolic blood
pressure
86 mm Hg 73 mm Hg .015
Serum
creatinine
2.4 mg/dL 1.7 mg/dL .025
eGFR 21 ml/min/1.72m2 42 ml/min/1.72 m2 .027
Percent decline
in preop
eGFR per
week
3.4 % / week 0.18 % / week  .0001
Proportion
with solitary
18% 13% .64kidneysContinued.
Variables Responders Nonresponders P value
Kidney Length 9.6 cm 9.8 cm .72
Kidney Width 5.3 cm 5.4 cm .20
Kidney Depth 5.0 cm 5.1 cm .70
Kidney Volume 123 cm3 129 cm3 .53
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Introduction: Contradictory outcomes exist for different methods of
carotid artery revascularization. Here we provide the comparative rates of
adverse events in patients after carotid endarterectomy (CEA), carotid artery
stenting (CAS) with distal protection (EPD), and CAS with flow reversal
technology (FRS) from a single institution by various specialists treating
carotid artery disease.
Methods: Procedural billing codes and the electronic medical records
of patients undergoing carotid artery revascularization for carotid artery
stenosis from February 2007 through March 2010 were utilized for data
collection. Primary outcome was the incidence of stroke, MI, or death after
CEA and CAS. The choice of therapy was determined by the individual
practitioner with some specialists providing both CAS and CEA (5/14).
Baseline characteristics were examined for effect on outcome. Planned
comparisons between and within groups were analyzed using 2, t tests, and
ANOVA as appropriate.
Results: There were 495 total procedures divided into carotid endar-
terectomies (226), CAS with EPD (216), and CAS with FRS (53). Preop-
erative comparisons of patient comorbidities were similar between cohorts.
Forty-two percent of these patients were symptomatic from their carotid
artery stenosis. Prior CEA was an indication for CAS over CEA (P  .001).
Significantly fewer patients undergoing CEAwere on preoperative antiplate-
let therapy (P .001) (Table I). There was no difference between groups in
the overall composite end point of death, stroke, andMI (4%, 5.1%, 0%; P
.1) or any individual major adverse event (Table II). Overall, CAS with EPD
had a statistically significant greater incidence of minor strokes when com-
pared to CEA (P  .031) which was driven by the increased stroke risk for
asymptomatic patients. Secondary endpoints occurred rarely (2%) as listed
in Table 3. There have been no reoperations or interventions in these
patients to date within this institution.
Conclusions: We have established a similar and low incidence of MI,
stroke, and death among patients undergoing CEA and CAS of whom
approximately 40%were symptomatic. The flow reversal system has provided
superior results in this series; however, its use was limited to 20% of the
carotid artery stenting procedures. Still zero adverse events in this cohort
make this an exciting technology that warrants a large-scale prospective
comparative study.
Table I. Patient characteristics
CEA
CAS 
EPD
CAS 
FRS P values
Overall
n 
226
n 
216
n 
53 Overall
CEA/
EPD
CEA/
FRS
Gender 
Female
41% 38% 42% .80 .55 .91
Age .62 .65 .49
Median
(years)
70 70 69
80 years 14% 21% 19%
Symptomatic 41% 45% 32.7% .27 .43 .26
Prior CEA 12% 29% 27% .001 .001 .017
Hypertension 94% 92% 86% .13 .50 .062
Hyperlipidemia 82% 87% 69% .014 .15 .046
Renal
Disease
9% 11% 2% .084 .46 .067
Prior CVA 29% 22% 17% .087 .090 .065
Prior TIA 31% 40% 46% .067 .058 .062
Diabetes 35% 41% 36% .44 .21 .85
Prior MI 15% 13% 21% .42 .63 .31
Plavix 35% 96% 96% .001 .001 .001therapy
